FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033791595> ?p ?o ?g. }

• W3033791595 endingPage "613" @default.
• W3033791595 startingPage "604" @default.
• W3033791595 abstract "Background Warfarin has been the oral anticoagulant of choice for the treatment of thromboembolic disease. However, upward of 50% of all new anticoagulant prescriptions are now for direct oral anticoagulants (DOAC). Despite this, outcome data evaluating preinjury anticoagulants remain scarce following traumatic brain injury (TBI). Our study objective is to determine the effects of preinjury anticoagulation on outcomes in older adults with TBI. Methods Patient data were obtained from 29 level 1 and 2 trauma centers from 2012 to June 30, 2018. Overall, 8312 patients who were aged 65 years or older, suffering a ground level fall, and with an Abbreviated Injury Scale (AIS) head score of ≥ 3 were identified. Patients were excluded if they presented with no signs of life or a traumatic mechanism besides ground level fall. Statistical comparisons were made using multivariable analyses with anticoagulant/antiplatelet use as the independent variable. Results Of the total patients with TBI, 3293 were on antiplatelet agents (AP), 669 on warfarin, 414 on warfarin + AP, 188 on DOACs, 116 on DOAC + AP, and 3632 on no anticoagulant. There were 185 (27.7%) patients on warfarin and 43 (22.9%) on a DOAC with a combined outcome of mortality or hospice as compared to 575 (15.8%) in the no anticoagulant group (p<0.001). After adjusting for patient factors, there was an increased risk of mortality or hospice in the warfarin (OR 1.60; 95% CI 1.27–2.01) and DOAC group (OR 1.67; 95% CI 1.07–2.59) as compared to no anticoagulant. Warfarin + AP was associated with an increased risk of mortality or hospice (OR 1.61; 95% CI 1.18–2.21) that was not seen with DOAC + AP (OR 0.93; 95% CI 0.46–1.87) as compared to no anticoagulant. Conclusions In older adults with TBI, preinjury treatment with warfarin or DOACs resulted in an increased risk of mortality or hospice whereas preinjury AP therapy did not increase risk. Future studies are needed with larger sample sizes to directly compare TBI outcomes associated with preinjury warfarin versus DOAC use." @default.
• W3033791595 created "2020-06-12" @default.
• W3033791595 creator A5042901119 @default.
• W3033791595 creator A5045516066 @default.
• W3033791595 creator A5052707281 @default.
• W3033791595 creator A5074520439 @default.
• W3033791595 creator A5083714013 @default.
• W3033791595 date "2020-07-01" @default.
• W3033791595 modified "2023-10-10" @default.
• W3033791595 title "Effect of Preinjury Oral Anticoagulants on Outcomes Following Traumatic Brain Injury from Falls in Older Adults" @default.
• W3033791595 cites W1214371988 @default.
• W3033791595 cites W1978424134 @default.
• W3033791595 cites W2033102959 @default.
• W3033791595 cites W2041727904 @default.
• W3033791595 cites W2041970819 @default.
• W3033791595 cites W2051001672 @default.
• W3033791595 cites W2054458452 @default.
• W3033791595 cites W2067838998 @default.
• W3033791595 cites W2085487386 @default.
• W3033791595 cites W2097854437 @default.
• W3033791595 cites W2102836206 @default.
• W3033791595 cites W2107876715 @default.
• W3033791595 cites W2136489990 @default.
• W3033791595 cites W2162508946 @default.
• W3033791595 cites W2174386486 @default.
• W3033791595 cites W2294236942 @default.
• W3033791595 cites W2337848138 @default.
• W3033791595 cites W2442489393 @default.
• W3033791595 cites W2496155895 @default.
• W3033791595 cites W2514335032 @default.
• W3033791595 cites W2555731020 @default.
• W3033791595 cites W2595085771 @default.
• W3033791595 cites W2595261167 @default.
• W3033791595 cites W2595786785 @default.
• W3033791595 cites W2608246596 @default.
• W3033791595 cites W2740482512 @default.
• W3033791595 cites W2750504927 @default.
• W3033791595 cites W2762043977 @default.
• W3033791595 cites W2771562059 @default.
• W3033791595 cites W2781675735 @default.
• W3033791595 cites W2787493763 @default.
• W3033791595 cites W2790916527 @default.
• W3033791595 cites W2794798533 @default.
• W3033791595 cites W2806615369 @default.
• W3033791595 cites W2886509534 @default.
• W3033791595 cites W2969428143 @default.
• W3033791595 cites W826970266 @default.
• W3033791595 doi "https://doi.org/10.1002/phar.2435" @default.
• W3033791595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32515829" @default.
• W3033791595 hasPublicationYear "2020" @default.
• W3033791595 type Work @default.
• W3033791595 sameAs 3033791595 @default.
• W3033791595 citedByCount "15" @default.
• W3033791595 countsByYear W30337915952021 @default.
• W3033791595 countsByYear W30337915952022 @default.
• W3033791595 countsByYear W30337915952023 @default.
• W3033791595 crossrefType "journal-article" @default.
• W3033791595 hasAuthorship W3033791595A5042901119 @default.
• W3033791595 hasAuthorship W3033791595A5045516066 @default.
• W3033791595 hasAuthorship W3033791595A5052707281 @default.
• W3033791595 hasAuthorship W3033791595A5074520439 @default.
• W3033791595 hasAuthorship W3033791595A5083714013 @default.
• W3033791595 hasBestOaLocation W30337915952 @default.
• W3033791595 hasConcept C118552586 @default.
• W3033791595 hasConcept C126322002 @default.
• W3033791595 hasConcept C127413603 @default.
• W3033791595 hasConcept C190385971 @default.
• W3033791595 hasConcept C194828623 @default.
• W3033791595 hasConcept C2426938 @default.
• W3033791595 hasConcept C2776301958 @default.
• W3033791595 hasConcept C2776567890 @default.
• W3033791595 hasConcept C2778205648 @default.
• W3033791595 hasConcept C2778661090 @default.
• W3033791595 hasConcept C2779161974 @default.
• W3033791595 hasConcept C2780645631 @default.
• W3033791595 hasConcept C2781017439 @default.
• W3033791595 hasConcept C3017944768 @default.
• W3033791595 hasConcept C42219234 @default.
• W3033791595 hasConcept C71924100 @default.
• W3033791595 hasConcept C78519656 @default.
• W3033791595 hasConcept C85004164 @default.
• W3033791595 hasConcept C98274493 @default.
• W3033791595 hasConceptScore W3033791595C118552586 @default.
• W3033791595 hasConceptScore W3033791595C126322002 @default.
• W3033791595 hasConceptScore W3033791595C127413603 @default.
• W3033791595 hasConceptScore W3033791595C190385971 @default.
• W3033791595 hasConceptScore W3033791595C194828623 @default.
• W3033791595 hasConceptScore W3033791595C2426938 @default.
• W3033791595 hasConceptScore W3033791595C2776301958 @default.
• W3033791595 hasConceptScore W3033791595C2776567890 @default.
• W3033791595 hasConceptScore W3033791595C2778205648 @default.
• W3033791595 hasConceptScore W3033791595C2778661090 @default.
• W3033791595 hasConceptScore W3033791595C2779161974 @default.
• W3033791595 hasConceptScore W3033791595C2780645631 @default.
• W3033791595 hasConceptScore W3033791595C2781017439 @default.
• W3033791595 hasConceptScore W3033791595C3017944768 @default.
• W3033791595 hasConceptScore W3033791595C42219234 @default.
• W3033791595 hasConceptScore W3033791595C71924100 @default.

• next